However, recent reports show effectiveness of an AP-1 small molecule inhibitors, often designed years earlier in cancer preclinical models, e.g., in head and neck or lung cancers [182,183], which may be yet included on maps of specific or combinational anti-cancer therapies. This evidence concerns the gene JUN and cancer.